Lurasidone
- Generic Name
- Lurasidone
- Brand Names
- Latuda
- Drug Type
- Small Molecule
- Chemical Formula
- C28H36N4O2S
- CAS Number
- 367514-87-2
- Unique Ingredient Identifier
- 22IC88528T
- Background
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
- Indication
Lurasidone is indicated for the treatment of schizophrenia in patients ≥13 years old. It is also indicated as a monotherapy for the treatment of bipolar depression in patients ≥10 years old, or in combination with lithium or valproate for the treatment of bipolar depression in adults.
- Associated Conditions
- Depression, Bipolar, Schizophrenia
A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2002-08-20
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 356
- Registration Number
- NCT00044044
- Locations
- 🇺🇸
Alexian Brothers Behavioral Health Hospital, Hoffman Estates, Illinois, United States
🇺🇸ClinSearch, Inc., Kenilworth, New Jersey, United States
🇺🇸Claghorn Lesem Research Clinic, Inc., Bellaire, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.